Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Operating Expenses (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Other Operating Expenses for 16 consecutive years, with -$87000.0 as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses changed N/A to -$87000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $182.6 million through Dec 2025, up 39.05% year-over-year, with the annual reading at -$382000.0 for FY2025, 107.14% down from the prior year.
  • Other Operating Expenses hit -$87000.0 in Q4 2025 for Ani Pharmaceuticals, up from -$295000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $99.2 million in Q2 2025 to a low of -$8.4 million in Q2 2021.
  • Historically, Other Operating Expenses has averaged $45.1 million across 5 years, with a median of $53.4 million in 2023.
  • Biggest five-year swings in Other Operating Expenses: crashed 124.47% in 2021 and later soared 672.32% in 2022.
  • Year by year, Other Operating Expenses stood at -$350000.0 in 2021, then surged by 13835.71% to $48.1 million in 2022, then soared by 46.85% to $70.6 million in 2023, then increased by 3.05% to $72.8 million in 2024, then plummeted by 100.12% to -$87000.0 in 2025.
  • Business Quant data shows Other Operating Expenses for ANIP at -$87000.0 in Q4 2025, -$295000.0 in Q3 2025, and $99.2 million in Q2 2025.